Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HTR2B | P41595 | 4/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23771986 | 0.87 | HTR2A (0.38) | HTR2AHTR2CHTR2BTUBB1NFE2L2 | |
| SCHEMBL13748809 | 0.85 | HTR2A (0.44) | HTR2AHTR2CHTR2BTUBB1NFE2L2 | |
| SCHEMBL16421053 | 0.82 | KCNH2 (0.31) | — | |
| SCHEMBL22570314 | 0.80 | HTR2A (0.42) | HTR2AHTR2CHTR2BNFE2L2LMNA | |
| SCHEMBL2955217 | 0.79 | CA2 (0.43) | TUBB1LMNAMAPK1HTTRAB9A | |
| SCHEMBL8220456 | 0.79 | NFE2L2 (0.44) | NFE2L2LMNAMAPK1CA12CA1 | |
| SCHEMBL19294287 | 0.79 | FFAR4 (0.34) | — | |
| SCHEMBL12871808 | 0.77 | CES2 (0.37) | — | |
| SCHEMBL12678823 | 0.76 | NQO2 (0.36) | HTR2AHTR2CHTR2BTUBB1NFE2L2 | |
| SCHEMBL15780820 | 0.76 | HTR2A (0.45) | HTR2AHTR2CHTR2BMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | HTR2A 1983/4885HTR2C 1115/4885HTR2B 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.